Investors

We are a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and branded injectable and inhalation products.  We currently manufacture and sell over 20 branded and generic products in the U.S. and are developing a portfolio of over 20 commercial injectable and inhalation products that primarily target markets with high technical barriers to entry.

More

 

More

Press Releases

Dec 29, 2020
Amphastar Announces Approval for Glucagon for Injection Kit, 1mg
RANCHO CUCAMONGA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg.
Dec 29, 2020
Amphastar Announces Approval for Glucagon for Injection Kit, 1mg
RANCHO CUCAMONGA, Calif. , Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg.
More

Events & Presentations

More events are coming soon.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

THIS CONFERENCE CALL MAY CONTAIN FORWARD-LOOKING STATEMENTS INCLUDING STATEMENTS RELATING TO AMPHASTAR PHARMACEUTICALS. THESE STATEMENTS ARE NOT HISTORICAL FACTS, BUT RATHER BASED ON AMPHASTAR PHARMACEUTICAL'S CURRENT EXPECTATIONS, ESTIMATES AND PROJECTIONS REGARDING AMPHASTAR PHARMACEUTICAL'S BUSINESS, OPERATIONS AND OTHER SIMILAR OR RELATED FACTORS. WORDS SUCH AS MAY, WILL, COULD, WOULD, SHOULD, ANTICIPATE, PREDICT, POTENTIAL, CONTINUE, EXPECTS, INTENDS, PLANS, PROJECTS, BELIEVES, ESTIMATES AND OTHER SIMILAR OR RELATED EXPRESSIONS ARE USED TO IDENTIFY THESE FORWARD-LOOKING STATEMENTS. THESE STATEMENTS ARE ONLY PREDICTIONS AND ARE SUCH ARE NOT GUARANTEES OF FUTURE PERFORMANCE. AND THEY INVOLVE RISKS, UNCERTAINTIES AND ASSUMPTIONS THAT ARE DIFFICULT OR IMPOSSIBLE TO PREDICT. ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS. AS A RESULT OF A NUMBER OF FACTORS INCLUDING THESE DESCRIBED FROM TIME TO TIME AND AMPHASTAR PHARMACEUTICALS' FILINGS WITH THE SEC.*

 

Copyright ©2021 Amphastar Pharmaceuticals, Inc.

Privacy      Terms & Conditions

This site is intended for residents of the United States